Developing best-in-class compounds to improve patient lives in high-value markets

Excellence in Medicinal Chemistry

At Motif, members of our team have developed blockbuster new drugs at the world’s leading pharmaceutical companies and are the named inventors on over 160 US-issued patents.  With our deep drug discovery and development expertise, we have unique proprietary insights to fix flaws of existing first-in-class (FIC) drugs and to design best-in-class (BIC) compounds.  We have partnered with two of the world’s leading drug discovery and development companies.  Together with a seasoned management team, Motif is uniquely positioned to rapidly develop optimal BIC compounds with Intellectual Property (IP) Protection.



Developing solutions for the antibiotic crisis

Our lead program is designed to produce broad-spectrum antibiotics with efficacy against gram-positive bacteria, including MRSA (methicillin-resistant Staphylococcus aureus) and other multi-drug resistant bacteria.  MRSA is now a leading cause of hospital acquired infections and a growing cause of infections in healthy people within the community.  Patients often fail to respond to conventional treatment, resulting in prolonged illness, costly hospitalizations, and greater risk of death.  In 2013, the Centers of Disease Control (CDC) reported that at least 2 million people became infected with bacteria that are resistant to antibiotics and at least 23,000 Americans died as a direct result of these infections – more than the annual number of deaths of people diagnosed with AIDS.

The global antibiotic market was valued at $41.5 billion in 2009 and is estimated to reach $65.5 billion in 2014.  Given the urgent need to find new antibiotics to address this problem, Motif has a dedicated effort in developing new best-in-class antibiotics, each targeting different and unique mechanisms of action to be effective against bacteria that are resistant to most currently available antibiotics.